<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORDRAN- flurandrenolide cream </strong><br><strong>CORDRAN- flurandrenolide ointment </strong><br>Aqua Pharmaceuticals<br></p></div>
<h1>Cordran<span class="Sup">®</span>  Cream <br> and<br> Cordran<span class="Sup">®</span> Ointment<br>  Flurandrenolide, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cordran<span class="Sup">®</span> (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One gram of flurandrenolide dissolves in 72 mL of alcohol and in 10 mL of chloroform. The molecular weight of flurandrenolide is 436.52.</p>
<p>The chemical name of flurandrenolide is Pregn-4-ene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-, (6α, 11β, 16α)-; its empirical formula is C<span class="Sub">24</span>H<span class="Sub">33</span>FO<span class="Sub">6</span>. The structure is as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-01.jpg"></div>
<p>Each gram of Cordran<span class="Sup">®</span>  Cream (flurandrenolide Cream, USP) contains 0.5 mg (1.145 µmol; 0.05%) or 0.25 mg (0.57 µmol; 0.025%) flurandrenolide in an emulsified base composed of cetyl alcohol, citric acid, mineral oil, polyoxyl 40 stearate, propylene glycol, sodium citrate, stearic acid, and purified water.</p>
<p>Each gram of Cordran<span class="Sup">®</span> Ointment (flurandrenolide Ointment, USP) contains 0.5 mg (1.145 µmol; 0.05%) or 0.25 mg (0.57 µmol; 0.025%) flurandrenolide in a base composed of white wax, cetyl alcohol, sorbitan sesquioleate, and white petrolatum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions.</p>
<p>The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Corticosteroids with anti-inflammatory activity may stabilize cellular and lysosomal membranes. There is also the suggestion that the effect on the membranes of lysosomes prevents the release of proteolytic enzymes and, thus, plays a part in reducing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pharmacokinetics</span>— The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</p>
<p></p>
<p>Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase percutaneous absorption.</p>
<p>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cordran<span class="Sup">®</span> (flurandrenolide, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Topical corticosteroids are contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of these preparations.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PREC"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-5.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">General</span>—Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in some patients.</p>
<p>Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.</p>
<p>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression using urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.</p>
<p>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, so that supplemental systemic corticosteroids are required.</p>
<p>Pediatric patients may absorb proportionately larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see <a href="#pediatric">Pediatric Use under PRECAUTIONS</a>).</p>
<p>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</p>
<p>In the presence of dermatologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Cordran should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-5.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Information for the Patient</span>—Patients using topical corticosteroids should receive the following information and instructions:</p>
<ol>
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</li>
<li>Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped in order to be occlusive unless the patient is directed to do so by the physician.</li>
<li>Patients should report any signs of local adverse reactions, especially under occlusive dressing.</li>
<li>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a patient being treated in the diaper area, because these garments may constitute occlusive dressings.</li>
<li>Do not use Cordran on the face, underarms, or groin areas unless directed by your physician.</li>
<li>If no improvement is seen within 2 weeks, contact your physician.</li>
<li>Do not use other corticosteroid-containing products while using Cordran without first consulting your physician.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-5.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Laboratory Tests</span>—The following tests may be helpful in evaluating the HPA axis suppression:</p>
<dl>
<dt> </dt>
<dd>Urinary-free cortisol test</dd>
<dt> </dt>
<dd>ACTH stimulation test</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-5.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Carcinogenesis, Mutagenesis, and Impairment of Fertility</span>—Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.</p>
<p>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.5"></a><p></p>
<h2></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-5.5.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Usage in Pregnancy — Pregnancy Category C—</span>Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corti-costeroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively for pregnant patients or in large amounts or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-5.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Nursing Mothers</span>—It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities <span class="Italics">not</span> likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-5.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pediatric Use</span>—Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than do mature patients because of a larger skin surface area to body weight ratio.</p>
<p>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
<p>Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:</p>
<dl>
<dt> </dt>
<dd>Burning</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></dd>
<dt> </dt>
<dd>Irritation</dd>
<dt> </dt>
<dd>Dryness</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">Hypertrichosis</span></dd>
<dt> </dt>
<dd>Acneform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span></dd>
<dt> </dt>
<dd>Hypopigmentation</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">Perioral dermatitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span></dd>
</dl>
<p>The following may occur more frequently with occlusive dressings:</p>
<dl>
<dt> </dt>
<dd>Maceration of the skin</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary infection</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">Skin atrophy</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">Striae</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">Miliaria</span></dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Postmarketing Adverse Reactions</h2>
<p class="First">The following adverse reactions have been identified during post approval use of flurandrenolide, USP.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Skin</span>:  <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">skin striae</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> and <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-7"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see <a href="#PREC">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day. For dry, scaly lesions, the ointment is applied as a thin film to affected areas 2 or 3 times daily.</p>
<p>Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.</p>
<p>Cordran<span class="Sup">®</span> (flurandrenolide, USP) should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cordran<span class="Sup">®</span>  Cream is supplied in aluminum tubes as follows:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="80%">
<tbody class="Headless">
<tr><td align="left" colspan="2">Cordran<span class="Sup">®</span>  Cream, 0.025%:</td></tr>
<tr>
<td align="left">  30 g</td>
<td align="left">(NDC 16110-034-30)</td>
</tr>
<tr>
<td align="left">  60 g</td>
<td align="left">(NDC 16110-034-60)</td>
</tr>
<tr>
<td align="left">  120 g</td>
<td align="left">(NDC 16110-034-12)</td>
</tr>
<tr><td align="left" colspan="2">Cordran<span class="Sup">®</span>  Cream, 0.05%:</td></tr>
<tr>
<td align="left">  15 g</td>
<td align="left">(NDC 16110-035-15)</td>
</tr>
<tr>
<td align="left">  30 g</td>
<td align="left">(NDC 16110-035-30)</td>
</tr>
<tr>
<td align="left">  60 g</td>
<td align="left">(NDC 16110-035-60)</td>
</tr>
<tr>
<td align="left">  120 g</td>
<td align="left">(NDC 16110-035-12)</td>
</tr>
</tbody>
</table>
<p>Cordran<span class="Sup">®</span> Ointment is supplied in aluminum tube as follows:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="80%">
<tbody class="Headless">
<tr><td align="left" colspan="2">Cordran<span class="Sup">®</span> Ointment, 0.05%:</td></tr>
<tr>
<td align="left">  15 g</td>
<td align="left">(NDC 16110-026-15)</td>
</tr>
<tr>
<td align="left">  30 g</td>
<td align="left">(NDC 16110-026-30)</td>
</tr>
<tr>
<td align="left">  60 g</td>
<td align="left">(NDC 16110-026-60)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Keep out of reach of children.</span></p>
<p>Storage</p>
<p>Keep tightly closed.</p>
<p>Protect from light.</p>
<p>Store at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F) [See USP controlled room temperature.].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>Revision:  08/2013</p>
<p>Manufactured by DPT Laboratories, San Antonio, TX 78215<br>For Aqua Pharmaceuticals, West Chester, PA 19380</p>
<p>140165</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 g Tube - 0.05%</h1>
<p class="First"><span class="Bold">60 g Tube<br>NDC 16110-035-60</span></p>
<p><span class="Bold Italics">Cordran<span class="Sup">®</span><br>Flurandrenolide Cream, USP</span><br><span class="Bold Italics">0.05%</span><span class="Bold">      Rx Only</span></p>
<p><span class="Bold Italics">FOR EXTERNAL USE ONLY - NOT FOR USE IN THE EYES</span></p>
<p><span class="Bold Italics">USUAL DOSAGE: </span>Apply to affected area 2 or 3 times a day. See package insert.</p>
<p>Each gram contains: flurandrenolide 0.5 mg (0.05%), cetyl alcohol,<br> citric acid, mineral oil, polyoxyl 40 stearate, propylene glycol, sodium citrate,<br>stearic acid and purified water. <br>
							Store at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C<br>(59° to 86°F) [See USP controlled room temperature].
						</p>
<p>Keep Tightly Closed and Protect from Light.</p>
<p><span class="Bold">IMPORTANT: </span>Do not use if seal has been punctured or is not visible. </p>
<p><span class="Bold">Cap is Not Child Resistant. Keep Away from Children.</span></p>
<p>See Crimp for Expiration Date and Lot No.<br><br>
							Manufactured by DPT Laboratories, San Antonio, TX 78215<br>
							For Aqua Phamraceuticals, West Chester, PA 19380</p>
<div class="Figure"><img alt="Principal Display Panel - 60 g Tube - 0.05%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 g Tube Carton - 0.05%</h1>
<p class="First"><span class="Bold">60 g Tube<br>NDC 16110-035-60</span></p>
<p><span class="Bold Italics">Cordran<span class="Sup">®</span><br>Flurandrenolide Cream, USP</span></p>
<p><span class="Bold Italics">0.05%   </span><span class="Bold Italics"> USUAL DOSAGE: </span><span class="Bold">Apply to affected area 2 or 3 times a day.   Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 60 g Tube Carton - 0.05%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 120 g Tube - 0.05%</h1>
<p class="First"><span class="Bold">120 g Tube<br>NDC 16110-035-12</span></p>
<p><span class="Bold Italics">Cordran<span class="Sup">®</span><br>Flurandrenolide Cream, USP</span></p>
<p><span class="Bold Italics">0.05%</span><span class="Bold">      Rx Only</span><br><span class="Bold">FOR EXTERNAL USE ONLY -<br> NOT FOR USE IN THE EYES</span></p>
<p><span class="Bold Italics">USUAL DOSAGE: </span>Apply to affected area<br> 2 or 3 times a day. See package insert.</p>
<p>Each gram contains:<br> flurandrenolide 0.5 mg (0.05%),<br> cetyl alcohol, citric acid, mineral oil,<br> polyoxyl 40 stearate, propylene glycol,<br> sodium citrate, stearic acid and purified water. <br>
							Store at 20° to 25°C (68° to 77°F) with<br> excursions permitted to 15° to 30°C<br>(59° to 86°F) [See USP controlled<br> room temperature].
						</p>
<p>Keep Tightly Closed and Protect from Light.</p>
<p><span class="Bold">IMPORTANT: </span>Do not use if seal has been punctured or is not visible. </p>
<p><span class="Bold">Cap is Not Child Resistant.<br> Keep Away from Children.</span></p>
<p>See Crimp for Expiration Date and Lot No.<br><br>
							Manufactured by DPT Laboratories, San Antonio, TX 78215<br>
							For Aqua Phamraceuticals, West Chester, PA 19380</p>
<div class="Figure"><img alt="Principal Display Panel - 120 g Tube - 0.05%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 120 g Tube Carton - 0.05%</h1>
<p class="First"><span class="Bold">120 g Tube<br>NDC 16110-035-12</span></p>
<p><span class="Bold Italics">Cordran<span class="Sup">®</span><br>Flurandrenolide Cream, USP</span></p>
<p><span class="Bold Italics">0.05%   </span><span class="Bold Italics"> USUAL DOSAGE: </span><span class="Bold">Apply to affected area 2 or 3 times a day.   Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 120 g Tube Carton - 0.05%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 g Tube - 0.05%</h1>
<p class="First"><span class="Bold">60 g Tube<br>NDC 16110-026-60</span></p>
<p><span class="Bold Italics">Cordran<span class="Sup">®</span><br>Flurandrenolide Ointment, USP</span></p>
<p><span class="Bold Italics">0.05%</span><span class="Bold">      Rx Only</span><br><span class="Bold">FOR EXTERNAL USE ONLY - NOT FOR USE IN THE EYES</span></p>
<p><span class="Bold Italics">USUAL DOSAGE: </span>Apply to affected area 2 or 3 times a day. See package insert.</p>
<p>Each gram contains: flurandrenolide 0.5 mg (0.05%), white wax, cetyl alcohol,<br>sorbitan sesquioleate and white petrolatum.</p>
<p>Store at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F)<br>[See USP controlled room temperature].</p>
<p>Keep Tightly Closed and Protect from Light.</p>
<p><span class="Bold">IMPORTANT: </span>Do not use if seal has been punctured or is not visible. </p>
<p><span class="Bold">Cap is Not Child Resistant. Keep Away from Children.</span></p>
<p>See Crimp for Expiration Date and Lot No.<br><br>
							Manufactured by DPT Laboratories, San Antonio, TX 78215<br>
							For Aqua Phamraceuticals, West Chester, PA 19380</p>
<div class="Figure"><img alt="Principal Display Panel - 60 g Tube - 0.05%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 g Tube Carton - 0.05%</h1>
<p class="First"><span class="Bold">60 g Tube<br>NDC 16110-026-60</span></p>
<p><span class="Bold Italics">Cordran<span class="Sup">®</span><br>Flurandrenolide Ointment, USP</span></p>
<p><span class="Bold Italics">0.05%   </span><span class="Bold Italics"> USUAL DOSAGE: </span><span class="Bold">Apply to affected area 2 or 3 times a day.   Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 60 g Tube Carton - 0.05%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0949773-c75f-4ef0-a69c-1abd978340d0&amp;name=cordran-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORDRAN 		
					</strong><br><span class="contentTableReg">flurandrenolide cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16110-035</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLURANDRENOLIDE</strong> (FLURANDRENOLIDE) </td>
<td class="formItem">FLURANDRENOLIDE</td>
<td class="formItem">0.5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYOXYL 40 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16110-035-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16110-035-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">120 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA012806</td>
<td class="formItem">10/18/1965</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORDRAN 		
					</strong><br><span class="contentTableReg">flurandrenolide ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16110-026</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLURANDRENOLIDE</strong> (FLURANDRENOLIDE) </td>
<td class="formItem">FLURANDRENOLIDE</td>
<td class="formItem">0.5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WHITE WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITAN SESQUIOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16110-026-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA012806</td>
<td class="formItem">10/18/1965</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aqua Pharmaceuticals
							(605425912)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">832224526</td>
<td class="formItem">ANALYSIS(16110-035, 16110-026), LABEL(16110-035, 16110-026), MANUFACTURE(16110-035, 16110-026), PACK(16110-035)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>becbd930-ea5f-11e3-ac10-0800200c9a66</div>
<div>Set id: a0949773-c75f-4ef0-a69c-1abd978340d0</div>
<div>Version: 6</div>
<div>Effective Time: 20140604</div>
</div>
</div> <div class="DistributorName">Aqua Pharmaceuticals</div></p>
</body></html>
